STN: 125518 Proper Name: talimogene laherparepvec Tradename: IMLYGIC Manufacturer: BioVex Inc., a wholly owned subsidiary of Amgen, Inc. Indication:
For the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.
Product Information
Supporting Documents
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
